(Q39946514)

English

In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines (English)

1 reference

Europe PubMed Central

15 September 2017

0 references

endometrial cancer

1 reference

based on heuristic

inferred from title

author name string

Anjali Gaikwad

1

1 reference

Europe PubMed Central

15 September 2017

Judith K Wolf

2

1 reference

Europe PubMed Central

15 September 2017

Jubilee Brown

3

1 reference

Europe PubMed Central

15 September 2017

Lois M Ramondetta

4

1 reference

Europe PubMed Central

15 September 2017

Judith A Smith

5

1 reference

Europe PubMed Central

15 September 2017

publication date

27 August 2008

1 reference

Europe PubMed Central

15 September 2017

Journal of Oncology Pharmacy Practice

1 reference

Europe PubMed Central

15 September 2017

15

1 reference

Europe PubMed Central

15 September 2017

1

1 reference

Europe PubMed Central

15 September 2017

35-44

1 reference

Europe PubMed Central

15 September 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Current treatment options for endometrial cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Emerging drugs for ovarian cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155208095141

21 January 2018

Identifiers

10.1177/1078155208095141

1 reference

Europe PubMed Central

15 September 2017

release_szldf4iw6zgtvhmudy6xk2qad4

1 reference

https://api.fatcat.wiki/v0/release/szldf4iw6zgtvhmudy6xk2qad4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39946514&oldid=1880714498"